Biomarkers such as PD-L1 expression in tumor tissues, tumor mutation burden (TMB), mismatch repair gene (MMR), and microsatellite instability (MSI) (9–21) could predict the prognosis of HCC patients receiving anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.